Mechanism
How Ipamorelin Works in the Research — one receptor, one clean GH pulse, one downstream axis.
From the ghrelin receptor on pituitary cells to the growth-hormone pulse and the IGF-1 messenger it's meant to drive.
In plain English
So, what does ipamorelin peptide do, step by step? Picture a switch on the cells of your pituitary — a gland the size of a pea at the base of your brain. That switch is the ghrelin receptor, normally flipped by your body's hunger hormone. Ipamorelin is a tiny five-amino-acid key shaped to fit that same switch [1]. When it docks, the cell opens its internal calcium gates and squirts out a burst of growth hormone (GH) [4]. GH then travels to the liver and is supposed to trigger a second messenger, IGF-1, which carries out a lot of GH's actual tissue work [4]. The clever part is what ipamorelin doesn't do: it flips the GH switch hard but barely touches the nearby stress-hormone switches [1]. That is the entire mechanism — one receptor, one clean pulse, one downstream relay. Below, each step is unpacked with the studies behind it.
What is ipamorelin peptide?
Ipamorelin is a wholly synthetic pentapeptide — five amino acids in the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2 [1]. It was built by modifying an older growth-hormone-releasing peptide, GHRP-1, removing a central dipeptide to sharpen its action [1]. Two of its building blocks are non-natural D-amino acids that make it resistant to the enzymes that would otherwise chop it up, and the position-1 building block (Aib) adds further stability [1]. The result is a small, durable molecule with one defining job: selectively releasing growth hormone [1]. It is not an endogenous human peptide — it is a designed mimic of how the hunger hormone ghrelin behaves at its receptor [1].
Step one: the ghrelin receptor and the GH pulse
The mechanism starts at GHS-R1a — the growth hormone secretagogue receptor type 1a, better known as the ghrelin receptor [4]. It sits on the pituitary's GH-making cells, the somatotrophs. When ipamorelin binds, it activates a Gq/PLC signaling cascade that raises intracellular calcium, and that calcium surge is what makes the cell release growth hormone [4]. In its founding study, this produced potent GH release in rat pituitary cells, anaesthetised rats, and conscious swine [1]. The receptor also appears on appetite-related neurons and, in preclinical work, on pancreatic islet cells — which is why ghrelin-receptor agonists carry appetite and metabolic effects alongside the GH effect [4].
Step two: why the pulse stays clean (selectivity)
Selectivity is the mechanistic feature that makes ipamorelin interesting. Older GHRPs released GH but also stimulated the adrenal axis (ACTH and cortisol) and raised prolactin [1]. Ipamorelin, even at more than 200 times its GH ED50, did not push ACTH or cortisol beyond what a plain GHRH signal produces [1]. In plain terms, the molecule activates the GH-release pathway hard while sparing the neighboring hormone pathways — a sharper, cleaner pulse than the first-generation peptides delivered [1]. This is the property every downstream claim and every community comparison ultimately points back to [1].
Step three: the GH-to-IGF-1 axis (and its asterisk)
Downstream, growth hormone is meant to drive the liver to produce IGF-1 (insulin-like growth factor 1), the messenger behind much of GH's tissue effect [4]. But here the mechanism comes with an honest asterisk: in short rodent studies, IGF-1 did not always rise even when ipamorelin clearly raised bone growth — a 15-day rat study showed skeletal growth with no measurable total-IGF-1 change [4]. In rats given a glucocorticoid, ipamorelin combined with the steroid did raise IGF-1 [8]. So the GH-to-IGF-1 relay is real but context-dependent, not a guaranteed one-to-one bump — a nuance the simple 'peptide raises IGF-1' framing skips [4][8].
What is cjc 1295 ipamorelin (two doors into the same axis)
On 'what is cjc 1295 ipamorelin': it is the pairing of ipamorelin with CJC-1295, and mechanistically the two enter the GH axis through different doors [10]. Ipamorelin works on the ghrelin receptor; CJC-1295 is a long-acting GHRH analog that works on the GHRH receptor [10]. Because the two receptors drive GH release by complementary routes, the steady GHRH-side signal from CJC-1295 and the pulsing ghrelin-side signal from ipamorelin are often combined — and pulsatile GH persists even under continuous GHRH-analog stimulation, which underpins that logic [11]. CJC-1295 alone produced 2- to 10-fold GH increases and sustained IGF-1 in healthy adults [10]. The combination's mechanism is coherent; its combined efficacy has never been trial-tested [10][3].